Works matching IS 11732563 AND DT 2017 AND VI 37 AND IP 3

Results: 9

Cost-Effectiveness Analysis of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation in Taiwan.

Published in:

Clinical Drug Investigation, 2017, v. 37, n. 3, p. 285, doi. 10.1007/s40261-016-0487-7

By:

Liu, Chieh-Yu;
Chen, Hui-Chun

Publication type:

Article

Quantifying the Exposure of Tapentadol Extended Release in Japanese Patients with Cancer Pain and Bridging Tapentadol Pharmacokinetics Across Populations Using a Modeling Approach.

Published in:

Clinical Drug Investigation, 2017, v. 37, n. 3, p. 273, doi. 10.1007/s40261-016-0482-z

By:

Zhang, Liping;
Yan, Xiaoyu;
Nobe, Sayori;
Zannikos, Peter;
Etropolski, Mila;
Nandy, Partha

Publication type:

Article

A Randomized, Single-Blind Trial of Clobetasol Propionate 0.05% Cream Under Silicone Dressing Occlusion Versus Intra-Lesional Triamcinolone for Treatment of Keloid.

Published in:

Clinical Drug Investigation, 2017, v. 37, n. 3, p. 295, doi. 10.1007/s40261-016-0484-x

By:

Nor, Norazirah;
Ismail, Rasimah;
Jamil, Adawiyah;
Shah, Shamsul;
Imran, Farah

Publication type:

Article

Evaluation of the Pharmacokinetic Interaction between Venetoclax, a Selective BCL-2 Inhibitor, and Warfarin in Healthy Volunteers.

Published in:

Clinical Drug Investigation, 2017, v. 37, n. 3, p. 303, doi. 10.1007/s40261-016-0485-9

By:

Salem, Ahmed;
Hu, Beibei;
Freise, Kevin;
Agarwal, Suresh;
Sidhu, Dilraj;
Wong, Shekman

Publication type:

Article

Cost-Effectiveness Comparison Between the Response-Guided Therapies and Monotherapies of Nucleos(t)ide Analogues for Chronic Hepatitis B Patients in China.

Published in:

Clinical Drug Investigation, 2017, v. 37, n. 3, p. 233, doi. 10.1007/s40261-016-0486-8

By:

Lai, Keng;
Zhang, Chi;
Ke, Weixia;
Gao, Yanhui;
Zhou, Shudong;
Liu, Li;
Yang, Yi

Publication type:

Article

Safety and Effectiveness of Sodium Stibogluconate and Paromomycin Combination for the Treatment of Visceral Leishmaniasis in Eastern Africa: Results from a Pharmacovigilance Programme.

Published in:

Clinical Drug Investigation, 2017, v. 37, n. 3, p. 259, doi. 10.1007/s40261-016-0481-0

By:

Kimutai, Robert;
Musa, Ahmed;
Njoroge, Simon;
Omollo, Raymond;
Alves, Fabiana;
Hailu, Asrat;
Khalil, Eltahir;
Diro, Ermias;
Soipei, Peninah;
Musa, Brima;
Salman, Khalid;
Ritmeijer, Koert;
Chappuis, Francois;
Rashid, Juma;
Mohammed, Rezika;
Jameneh, Asfaw;
Makonnen, Eyasu;
Olobo, Joseph;
Okello, Lawrence;
Sagaki, Patrick

Publication type:

Article

Effect of Multiple Oral Doses of the Potent CYP3A4 Inhibitor Clarithromycin on the Pharmacokinetics of a Single Oral Dose of Vonoprazan: A Phase I, Open-Label, Sequential Design Study.

Published in:

Clinical Drug Investigation, 2017, v. 37, n. 3, p. 311, doi. 10.1007/s40261-016-0488-6

By:

Jenkins, Helen;
Jenkins, Richard;
Patat, Alain

Publication type:

Article

Pharmacokinetic Profile and Tolerability of Liposomal Bupivacaine Following a Repeated Dose via Local Subcutaneous Infiltration in Healthy Volunteers.

Published in:

Clinical Drug Investigation, 2017, v. 37, n. 3, p. 249, doi. 10.1007/s40261-017-0495-2

By:

Rice, David;
Heil, Justin;
Biernat, Lukasz

Publication type:

Article

Factors Related to the Glucose-Lowering Efficacy of Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review and Meta-Analysis Focusing on Ethnicity and Study Regions.

Published in:

Clinical Drug Investigation, 2017, v. 37, n. 3, p. 219, doi. 10.1007/s40261-016-0478-8

By:

Fujita, Kayo;
Kaneko, Masayuki;
Narukawa, Mamoru

Publication type:

Article